Oregon Public Employees Retirement Fund Sells 400 Shares of HCA Healthcare, Inc. $HCA

Oregon Public Employees Retirement Fund decreased its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 2.6% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,950 shares of the company’s stock after selling 400 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in HCA Healthcare were worth $5,727,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in HCA. Nuveen LLC purchased a new position in HCA Healthcare in the 1st quarter worth approximately $569,217,000. Pacer Advisors Inc. boosted its position in shares of HCA Healthcare by 6,237.9% during the first quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company’s stock worth $466,815,000 after acquiring an additional 1,329,618 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in HCA Healthcare by 83.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company’s stock valued at $829,104,000 after acquiring an additional 1,091,416 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of HCA Healthcare by 49.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company’s stock valued at $615,583,000 after purchasing an additional 587,036 shares during the last quarter. Finally, Abdiel Capital Advisors LP purchased a new stake in shares of HCA Healthcare in the first quarter worth about $164,835,000. Institutional investors own 62.73% of the company’s stock.

HCA Healthcare Price Performance

Shares of NYSE:HCA opened at $410.71 on Tuesday. HCA Healthcare, Inc. has a 1 year low of $289.98 and a 1 year high of $439.01. The firm has a market capitalization of $96.10 billion, a PE ratio of 17.26, a price-to-earnings-growth ratio of 1.31 and a beta of 1.40. The business has a 50 day simple moving average of $406.07 and a two-hundred day simple moving average of $376.56.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings results on Friday, July 25th. The company reported $6.84 EPS for the quarter, topping the consensus estimate of $6.20 by $0.64. The company had revenue of $18.61 billion for the quarter, compared to the consensus estimate of $18.49 billion. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The firm’s revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the firm posted $5.50 EPS. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. Equities research analysts expect that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Tuesday, September 16th were issued a $0.72 dividend. The ex-dividend date was Tuesday, September 16th. This represents a $2.88 dividend on an annualized basis and a yield of 0.7%. HCA Healthcare’s payout ratio is currently 12.11%.

Insider Activity

In other HCA Healthcare news, EVP Michael S. Cuffe sold 3,836 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $418.84, for a total value of $1,606,670.24. Following the completion of the sale, the executive vice president directly owned 31,503 shares in the company, valued at $13,194,716.52. This trade represents a 10.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

HCA has been the topic of several recent research reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of HCA Healthcare in a report on Wednesday, October 8th. Truist Financial upped their price target on shares of HCA Healthcare from $390.00 to $415.00 and gave the company a “buy” rating in a research note on Wednesday, July 16th. UBS Group set a $465.00 target price on shares of HCA Healthcare in a report on Wednesday, October 8th. Barclays boosted their price objective on HCA Healthcare from $390.00 to $445.00 and gave the stock an “overweight” rating in a research note on Thursday, September 18th. Finally, Wells Fargo & Company lifted their target price on HCA Healthcare from $375.00 to $412.00 and gave the stock an “equal weight” rating in a report on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $422.31.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.